Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma

• Published in: Scientific reports Vol. 14; no. 1; pp. 15947 - 11
• Main Authors: Okita, Riki, Senoo, Tomoya, Mimura-Kimura, Yuka, Mimura, Yusuke, Murakami, Tomoyuki, Ikeda, Eiji, Okada, Masanori, Inokawa, Hidetoshi, Aoe, Keisuke
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10.07.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67; 631/67/1641; 631/67/1857; 631/67/327; 631/67/580; 692/4028; Apoptosis; Cell death; CTLA-4 protein; Cytotoxicity; Humanities and Social Sciences; Immune checkpoint inhibitors; Immune checkpoint molecule; Immunoassays; Isoforms; Lymphocytes; Lymphocytes T; Mesothelioma; multidisciplinary; Observational studies; PD-1 protein; PD-L1 protein; Pleural effusion; Pleurisy; Science; Science (multidisciplinary); TGF-β; Transforming growth factor-b; Transforming growth factor-b1; Tumor immune microenvironment; Pleural effusion; Mesothelioma; Tumor immune microenvironment; TGF-β; Immune checkpoint molecule
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-66189-5

The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and PD-1 ligand 1 (PD-L1) using enzyme-linked immunosorbent assays; three TGF-β isoforms were measured via multiplex assay in PE of patients with fibrinous pleuritis (FP) or MPM, to assess relationships between the levels of six molecules, clinicopathological characteristics, and efficacy of immune checkpoint inhibitors. Soluble forms of CTLA-4, PD-L1, PD-1, TGF-β 1 , TGF-β 2 , and TGF-β 3 were variably produced in PE of FP (n = 34) and MPM (n = 79); we found significant relationships between the six molecules and clinicopathological features. Although none of the three soluble immune checkpoint molecules showed diagnostic or prognostic effects in patients with MPM, TGF-β 2 level in PE is a useful differential diagnostic marker between FP and MPM. Both TGF-β 1 and TGF-β 3 levels are promising prognostic markers for MPM. Moreover, we found that higher baseline levels of PD-1 soluble forms predicted the response to anti-PD1 monotherapy. Our findings identify novel diagnostic, prognostic, and predictive biomarkers for anti-PD1 therapy in patients with MPM.